Anti human lc3b nb100 2220 antibody

A549 and MEF cells were cultured in DMEM with 10 % FBS and 1 % penicillin/streptomycin (HyClone). MCF‐10A cells were cultured in DMEM: F12 (1 : 1) (HyClone, Thermo Fisher Scientific, Waltham, MA, USA) supplied with 1 % penicillin/streptomycin (HyClone), 5 % horse serum (HyClone), 0.1 % insulin solution (Millipore/Sigma, St. Louis, MO, USA), 0.01 % cholera toxin (Millipore/Sigma), 0.025 % hydrocortisone (ACROS/Thermo Fisher) and 0.02 % epidermal growth factor (Life Technologies/Invitrogen, Carlsbad, CA, USA). Antibodies used in this study are as follows: PARP (#9542S) and pChk1 (Ser‐345, #2348S) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti‐human LC3B (#NB100‐2220) antibody was obtained from Novus Biologicals (Centennial, CO, USA). Anti‐ATR (#SC‐1887), anti‐UHRF1 (#SC‐373750) and anti‐Chk1 (#SC‐56291) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti‐GAPDH (#60004) was from Proteintech (Rosemont, IL, USA). HRP conjugated secondary antibodies were purchased from Thermo/Invitrogen. DMSO (D8418) was purchased from Millipore/Sigma (St. Louis, MO, USA). Thiazolyl blue tetrazolium bromide (MTT) was purchased from BioTechne/Tocris (#5224). Camptothecin (CPT, 276721000) was purchased from Acros organics (Geel, Belgium).